Samsung Biologics, PharmAbcine Enter Antibody Pact

Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacture of PMC-402 pipeline, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders. Samsung will provide the full scope of services from cell line development, process development, cGMP clinical manufacturing to IND filing support.

Olinvacimab is PharmAbcine’s lead molecule currently in phase II trials for a combination therapy to treat cancer with Merck's Keytruda.

According to PharmAbcine, PMC-402 is expected to enhance the delivery of immune cells and cancer therapeutics to treat tumor cells via active normalization of leaky blood vessels. Attributable to its vessel normalization characteristics, PharmAbcine plans to expand the indication to eye diseases such as wAMD (wet age-related macular degeneration) and DR (diabetic retinopathy).

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.